Abstract
Background Subthalamic nucleus deep brain stimulation is a well-established treatment for patients with Parkinson’s disease. Previous acute challenge studies suggested that short pulse widths might increase the therapeutic window while maintaining motor symptom control.
Objectives To investigate in patients with Parkinson’s disease and nucleus subthalamicus deep brain stimulation (STN-DBS) whether short pulse width stimulation with 30µs maintains equal motor control as conventional 60µs stimulation over a period of 4 weeks.
Methods In this monocentric, double-blinded, randomized crossover trial, 30 patients with Parkinson’s disease and STN-DBS were enrolled and assigned to 4 weeks of stimulation with 30µs and 4 weeks of stimulation with 60µs in randomized order (German Clinical Trials Register No. DRKS00017528). The primary outcome was the difference in motor symptom control as assessed by a motor diary. Secondary outcomes included energy consumption measures, non-motor effects, side-effects, and quality of life.
Results A total of 24 patients were included in the final analysis. There was no difference in motor symptom control between the two treatment conditions. Concerning secondary outcomes there was no difference in energy consumption, non-motor symptoms, side-effects, or quality of life. On the individual level, patients preferring 30µs tended to be more dyskinetic in the 60µs setting, whereas patients preferring 60µs experienced more off-time in the 30µs setting.
Conclusions Short pulse width settings (30µs) provide equal motor symptom control as conventional (60µs) stimulation without significant differences in energy consumption. Future studies are warranted to evaluate a potential benefit of short pulse width settings in patients with pronounced dyskinesia.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
German Clinical Trials Register No. DRKS00017528
Funding Statement
No external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the University of Cologne approved the trial (vote: 19-1233) and it was conducted under the declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosure/Conflict of Interest concerning the research related to the manuscript: None
Funding sources for the study: JNPS and TAD were supported by the Cologne Clinician Scientist Program (CCSP)/Faculty of Medicine/University of Cologne. Funded by the German Research Foundation (DFG, FI 773/15-1). JCB and VVV were funded by the Deutsche Forschungsgemeinschaft, German Research Foundation (Project-ID: 431549029 – SFB 1451).
Data Availability
Data is available upon reasonable request to the authors.
Abbreviations
- BCI
- Battery Charge Index,
- CPP
- Charge per pulse,
- NMSQ
- Non-motor symptoms questionnaire,
- PD
- Parkinson’s disease,
- PDQ-39 SI
- Parkinson’s disease questionnaire 39-Item Quality of Life Questionnaire Summary Index,
- PW30
- trial condition with 30µs,
- PW60
- trial condition with 60µs,
- STN-DBS
- subthalamic nucleus deep brain stimulation,
- TEED
- total electrical energy delivered,
- UPDRS
- Unified Parkinson’s disease rating scale,
- VAS
- Visual analog scale
